Biomaterials have been extensively developed and applied in medical devices. Among these materials, bioabsorbable polymers have attracted special attention for orthopedic applications where a transient existence of an implant can provide better results, when compared with permanent implants. Chitosan, a natural biopolymer, has generated enormous interest due to its various advantages such as biocompatibility, biodegradability and osteoconductive properties. In this paper, an assessment of the potential of a developed innovative production process of 3D solid and dense chitosan-based products for biomedical applications is performed and presented. Therefore, it starts with a brief explanation of the technology, highlighting its main features. Then, several potential applications and their markets were identified and assessed. After choosing a primary application and market, its potential as well as its uncertainties and risks were identified. A business model suggesting how to materialize the value from the application was sketched. After that, a brief description of the market as well as the identification of the main competitors and their distinctive features was made. The supply chain analysis and the go-to-market strategy were the following steps. In the end, a final recommendation based on the assessment of the information was prepared.
Información de la revista
Vol. 26. Núm. 2.
Páginas 77-88 (julio - diciembre 2014)
Vol. 26. Núm. 2.
Páginas 77-88 (julio - diciembre 2014)
Acceso a texto completo
Competitiveness of chitosan-based implants
Visitas
2788
Nuno Guitian Oliveiraa,b,c,
, Luís F.V. Pintob, Luís Reisa, Alexandra Rodriguesa,d
Autor para correspondencia
a ICEMS, Instituto Superior Técnico, University of Lisbon, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
b Altakitin S.A., Rua José Gomes Ferreira, Arm. D, 2660-360 São Julião do Tojal, Lisboa, Portugal
c MIT Portugal Program, IST-Tagus Park, Av. Professor Cavaco Silva, 2744-016 Porto Salvo, Portugal
d GI-MOSM, Instituto Superior de Engenharia de Lisboa, ISEL, Rua Conselheiro Emídio Navarro, 1959-007 Lisboa, Portugal
Información del artículo
Abstract
Keywords:
chitosan
bioabsorbable implants
orthopedic applications
go-to-market strategy.
El Texto completo está disponible en PDF
References
[1]
H. Park, J.S. Temenoff, A.G. Mikos, in: F. Bronner, M.C. Farach-Carson, A.G. Mikos (Eds.), Engineering of Functional Skeletal Tissues, Springer London, 2007, pp. 55-68.
[2]
J.M. Anderson.
J Mater. Sci. Mater. Med, 17 (2006), pp. 1025
[5]
MarketsandMarkets, Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] – Global Forecasts to 2017, marketsandmarkets.com, 2013.
[7]
C. Gardner, T. Acharya, D. Yach.
Health Aff, 26 (2007), pp. 1052
[9]
NCBI, Literature, PubMed, in: http://www.ncbi.nlm.nih.gov/pubmed/?term=chitosan.
[10]
N. Guitian Oliveira, A. Rodrigues, L. Reis, L.F.V. Pinto.
J. Chitin Chitosan Sci, 1 (2013), pp. 210
[11]
N. Guitian Oliveira, T. Sirgado, L. Reis, L.F.V. Pinto, C.L. da Silva, F.C. Ferreira, A. Rodrigues.
J. Mech. Behav. Biomed. Mater, 40 (2014), pp. 413
[13]
J.L. Bower, C.M. Christensen.
Harv. Bus. Rev, 73 (1995), pp. 43
[14]
Q. Ao, C.-K. Fung, A.Y.-P. Tsui, S. Cai, H.-C. Zuo, Y.-S. Chan, D.K.-Y. Shum.
Biomaterials, 32 (2011), pp. 787
[15]
K. Haastert-Talini, S. Geuna, L.B. Dahlin, C. Meyer, L. Stenberg, T. Freier, C. Heimann, C. Barwig, L.F.V. Pinto, S. Raimondo, G. Gambarotta, S.R. Samy, N. Sousa, A.J. Salgado, A. Ratzka, S. Wrobel, C. Grothe.
Biomaterials, 34 (2013), pp. 9886
[17]
J.P. Wilkerson, J.E. Zvijac, J.W. Uribe, M.R. Schürhoff, J.B. Green.
J. Shoulder Elbow Surg, 12 (2003), pp. 117
[19]
Experts I 2011 Orthopedic Implants: A Global Market Overview 197.
[20]
MarketsandMarkets, Orthopedic Devices Market (Forecast to 2016), marketsandmarkets.com, 2011.
[21]
MarketsandMarkets, Global Spinal Implants and Surgical Devices Market - by Technology (Spinal Fusion & Fixation, Non-Fusion, Spinal Decompression, Vertebral Compression Fracture Repair & Spine Biologics), by Products - Trends, Competitive Analysis & Forecasts till 2017, marketsandmarkets.com, 2012.
[23]
T. Taylor, Spine, InnerBody, in: http://www.innerbody.com/image/skel05.html.
[25]
F. Costa, M. Sassi, A. Ortolina, A. Cardia, R. Assietti, A. Zerbi, M. Lorenzetti, F. Galbusera, M. Fornari.
Eur. Spine J, 20 (2011), pp. S46
[26]
Spine Center, Fusion with Interbody Cages, University of Maryland Medical Center, 2013.
[27]
R.W. Haid, C.L. Branch, J.T. Alexander, J.K. Burkus.
Spine J, 4 (2004), pp. 527
[28]
P.F. Ullrich Jr, Spine-health, in: http://www.spine- health.com/treatment/spinal-fusion/interbody-cages-spine- fusion (2004).
[30]
H. Kang, S.J. Hollister, F. La Marca, P. Park, C.-Y. Lin.
J. Biomech. Eng, 135 (2013), pp. 1
[31]
Y.-S. Kim.
Clin. Neurol. Neurosur, 99 (1997), pp. S108
[32]
C. Benjamin Ma, Spinal fusion, U.S. National Library of Medicine, 2013.
[33]
J.-Y. Ding, S. Qian, L. Wan, B. Huang, L.-G. Wang, Y. Zhou.
Arch. Orthop. Trauma Surg, 130 (2010), pp. 565
[34]
R.C. Sasso, SpineUniverse, in: http://www.spineuniverse.com/professional/technology/surg ical/thoracic/screws-cages-or-both, 2012.
[35]
P.F. Ullrich Jr, Spine-health, in: http://www.spine- health.com/treatment/back-surgery/cervical-spine-surgery (2010).
[36]
Rothman Institute, in: http://www.rothmaninstitute.com/specialties/treatments/fusi on-for-cervical-thoracic-and-lumbar-trauma.
[37]
F. Galbusera, H. Schmidt, H.-J. Wilke.
Eur. Spine J, 21 (2012), pp. 455
[39]
Medical Multimedia Group, LLC, in: http://www.eorthopod.com/posterior-lumbar-interbody- fusion/topic/167.
[40]
R.C. Sasso, SpineUniverse, in: http://www.spineuniverse.com/professional/research/technol ogy/surgical/lumbar/biomechanics-lumbosacral-fusion, 2012.
[41]
J.D. Coe.
Neurosurg. Focus, 16 (2004), pp. 31S
[42]
D. Bludovsky, M. Choc.
Eur. Cell. Mater, 11 (2006), pp. 33
[44]
F. El Masri, E. Sapin de Brosses, K. Rhissassi, W. Skalli, D. Mitton.
Comput. Methods Biomech. Biomed. Engin, 15 (2012), pp. 23
[45]
European Commission, Medical Devices, in: http://ec.europa.eu/health/medical- devices/faq/market_en.htm.
[46]
TheSPINEMarketGroup.com, in: http://www.thespinemarketgroup.com/p/market.html.
[47]
A. Osterwalder, Y. Pigneur, A. Smith.
Business Model Generation.
1st Ed, Wiley, (2010),
[48]
Strategyzer AG, The Business Model Canvas, in: http://www.businessmodelgeneration.com/canvas/bmc.
[49]
K. Ulrich, S.D. Eppinger.
Product Design and Development.
3rd ed., McGraw-Hill, (2003),
[50]
American Academy of Orthopaedic Surgeons, in: http://orthoinfo.aaos.org/topic.cfm?topic=A00502, 2010.
[51]
Zimmer, BAK/C® Anterior Cervical Interbody Fusion System, in: http://www.zimmer.com/medical- professionals/products/spine/bak-anterior-cervical- interbody-fusion.html
[52]
Stryker, Ray Threaded Fusion Cage, in: http://www.europe.stryker.com/index/st_pag_medic- home/st_pag_detailed-product-info/st_pag_spinal- implants/eu_pag_spine-interbody/eu_pag_spine-ray- threaded-fusion-cage.htm.
[53]
T.A. Zdeblick, J.K. Burkus, LT-CAGE Lumbar Tapered Fusion Device, Medtronic Sofamor Danek, USA, 2000.
[54]
Medtronic, Infuse Bone Graft/LT-Cage Lumbar Tapered Fusion Device, in: http://www.medtronic.com/for- healthcare-professionals/products-therapies/spinal/bone- graft-options/infuse-bone-graft/, 2010.
[55]
U.S. National Institutes of Health, in: https://clinicaltrials.gov/ct2/show/NCT00215319.
[56]
P.W. Pavlov, M. Spruit, M. Havinga, P.G. Anderson, J. van Limbeek, W.C. Jacobs.
Eur. Spine J, 9 (2000), pp. 224
[57]
LawyersandSettlements.com, Medtronic Infuse Bone Graft Hot Leg. Issues, 2014.
[58]
R.D. Dickerman, A.S. Reynolds, B. Morgan.
Int. Orthop, 32 (2008), pp. 717
[59]
P.F. Ullrich Jr, Spine-health, in: http://www.spine- health.com/treatment/spinal-fusion/allograft-cadaver-bone- a-tissue-bank (2009).
[61]
P.I.J.M. Wuisman, T.H. Smit.
Eur. Spine J, 15 (2006), pp. 133
[62]
D. Mukherjee, W. Pietrzak.
J. Craniofac. Surg, 22 (2011), pp. 679
[63]
C.R. Lippman, M. Hajjar, B. Abshire, G. Martin, R.W. Engelman, D.W. Cahill.
Neurosurg. Focus, 16 (2004), pp. E4
[64]
A.R. Vaccaro, K. Singh, R. Haid, S. Kitchel, P. Wuisman, W. Taylor, C. Branch, S. Garfin.
Spine J, 3 (2003), pp. 227
[67]
J.Y. Lazennec, A. Madi, M. a Rousseau, B. Roger, G. Saillant.
Eur. Spine J, 15 (2006), pp. 1545
[68]
M.A. Slivka, D.B. Spenciner, H.B. Seim, W.C. Welch, H.A. Serhan, A.S. Turner.
Spine, 31 (2006), pp. 2772
[69]
T.H. Smit, T.A. Engels, P.I.J.M. Wuisman, L.E. Govaert.
Spine, 33 (2008), pp. 14
[70]
A. Smith, M. Arginteanu, A. Steinberger, M. Camins.
Spine J, 10 (2010), pp. 94S
[71]
T.U. Jiya, T. Smit, B.J. van Royen, M. Mullender.
Eur. Spine J, 20 (2011), pp. 618
[72]
T.H. Smit, T. a P. Engels, S.H.M. Söntjens, L.E. Govaert.
J. Mater. Sci. Mater. Med, 21 (2010), pp. 871
[73]
F. Kandziora, R. Pflugmacher, M. Scholz, T. Eindorf, K.J. Schnake, N.P. Haas.
Spine, 29 (2004), pp. 1845
[74]
D.W. Cahill, G.J. Martin, M.V. Hajjar, W. Sonstein, L.B. Graham, R.W. Engelman.
J. Neurosurg. Spine, 98 (2003), pp. 195
[75]
M. van Dijk, T.H. Smit, M.F. Arnoe, E.H. Burger, P.I. Wuisman.
Eur. Spine J, 12 (2003), pp. 34
[78]
Symmetrics Group, A Go-To-Market Strategy Primer, in: http://symmetricsgroup.com/a-go-to-market-strategy- primer/, 2012.
[80]
R.P. Patel, A Patent Portfolio Development Strategy for Start-Up Companies, Fenwick & West LLP, USA, 2002.
[81]
M.J. Shuster, H. Su, S. Blaug.
Nat. Biotechnol, 21 (2003), pp. 701
[82]
D.S. Couto, L. Perez-Breva, P. Saraiva, C.L. Cooney.
Adv. Drug Deliv. Rev, 64 (2012), pp. 69
Copyright © 2015. Sociedade Portuguesa de Materiais (SPM)